Gracell (GRCL): יחס חוב לטווח ארוך להון

Gracell Biotechnologies is protected by exclusive patents for the rapid creation of therapeutic cells in the US and China, operating within the strict frameworks of the FDA and NMPA. This historical price chart demonstrates the asset's dynamics, with the indicator standing at 0.02. The company drives innovation through partnerships with global clinics. A proprietary digital production system ensures a technological leap and cost reductions, creating a powerful competitive barrier.

Gracell Biotechnologies dominates the rapid CAR-T therapy creation segment thanks to its FasTCAR platform. This indicator digitizes the cost of scaling such innovations through the long-term debt-to-equity ratio. The metric measures the business's degree of dependence on external borrowings with a term exceeding one year. This allows for an assessment of the balance between financial stability and the risk of underutilizing leverage. By analyzing the long-term debt-to-equity profile, an investor determines the trajectory of the capital structure transformation.